Las mutaciones del gen KRAS reprograman las modificaciones m6A del ARN para impulsar la evasión inmunitaria dependiente de CD73 en el cáncer colorrectal.

This study investigated how KRAS mutations, common in colorectal cancer, affect the tumor's ability to evade the immune system. The researchers looked at a specific modification of RNA called m6A (N6-methyladenosine).

The study found that KRAS mutations cause changes in m6A patterns. Specifically, they increase the amount of m6A on the messenger RNA (mRNA) for a protein called CD73. This increase makes the CD73 mRNA more stable, leading to higher levels of the CD73 protein. The researchers identified specific molecules (METTL3 and TEAD4) involved in adding these m6A marks. They also found that blocking METTL3 in laboratory models (syngeneic tumors) slowed tumor growth and improved the immune response against the tumor, specifically increasing certain immune cells (CD8⁺ T-cells and NK-cells), and this effect depended on CD73. Blocking METTL3 also worked better with existing immunotherapies (anti-PD-1) and drugs targeting CD73.

This research suggests that KRAS mutations use m6A modification to increase CD73 levels, which helps the tumor hide from the immune system. This is a laboratory finding, using cell cultures and mouse models. It is not yet known if these results will apply to people with colorectal cancer.

This study identifies METTL3 as a potential target for new therapies in colorectal cancer patients whose tumors have KRAS mutations. However, this is very early research. Much more work, including clinical trials in humans, would be needed to determine if targeting METTL3 is safe and effective for patients. It does not change current treatment recommendations.